Singulex, Inc., a Alameda, CA-based provider of Single Molecule Counting (SMC™) technology for scientific discovery and clinical testing services, closed a $55m financing.
It includes a debt facility for up to $40m from Oxford Finance and Silicon Valley Bank and $15m equity financing (closed in June 2013).
The company intends to use the funds to advance the development and commercialization of a global in vitro diagnostics business based on its SMC technology.
Led by Guido Baechler, President and Chief Executive Officer, Singulex has developed a proprietary SMC platform which enables physicians to individualize treatment strategies, monitor effectiveness of therapy and encourage patient adherence through feedback for for chronic diseases such as cardiovascular disease, Alzheimer’s, arthritis and diabetes. The company’s CLIA-certified laboratory offers a menu of advanced cardiovascular disease testing to physicians in the U.S.
FinSMEs
26/09/2013